Category: News

Southern Research Testing New Cost-Effective Methods for System Performance in Extreme Cold Conditions

When the Southern Research Engineering Division talks about testing materials in extreme environments, it usually is referring to measuring properties at very high temperatures up to 5500 °F.  However,  going hot isn’t the only extreme environment that modern materials experience.  Space exploration often results in the need for systems that perform at incredibly cold temperatures.  Applications include things like fuel tanks for propulsion systems that hold liquid oxygen at -423 °F and space telescopes that orbit far from the earth where they are shaded from the sun and can reach temperatures of -442 °F.

Mechanical testing at very low temperatures, or cryogenic temperatures, has historically been done by cooling materials using liquid cryogens such as liquid nitrogen (LN2) and liquid helium (LHe).  That process involves getting liquid cryogens in big vacuum flasks and spraying the cryogen on the test setup.  A single experiment can take a lot of cryogen to cool the material.  LN2 is inexpensive and readily available.  It can cool down to -320 °F and for tests at and above that temperature, cooling with LN2 remains a good choice.  However, for temperature below -320 °F, LHe is required.  There is a limited world-wide supply of LHe and in recent years it has quadrupled in price and become difficult to source.  A single mechanical test at -423 °F can take as much as two or three thousand dollars’ worth of LHe.  The combination of cost and availability of LHe has made testing below -320 °F difficult and expensive.

The difficulties in testing with LHe has led Southern Research to conduct an Internal Research and Development (IR&D) project to consider alternatives to using LHe liquid cryogen to conduct super-cold material tests.  The approach that has been developed uses a unique device known as a cryo-cooler.  A cryo-cooler is a mechanical compressor device that can cool the tip of a cold head down to -453 °F.  They have become much more common in recent years since they are used to cool the superconducting magnets in MRI units at almost every hospital.  At -453 °F, the cryo-cooler doesn’t have much cooling capacity, meaning that it cannot overcome much heat load.  Thus, the challenge to use a cryo-cooler to conduct tests at extremely cold temperatures is to design a system that thermally attaches the cold head to the material while minimizing the heat conducted into the test setup.

To reduce the heat load from convection, the test must be conducted in a vacuum.  Loads that are applied to the material must be through fixtures made of extremely low thermal conductivity material so as not to conduct heat from outside the vacuum chamber.  Finally, the test setup must be wrapped in multiple layer insulation (MLI) to prevent heating the material by radiation from the surroundings.  MLI is typically made of aluminum or silver coated thin film to reflect radiant energy.  Those that have seen or remember the lunar Landing Module from the Apollo missions will recall that it was wrapped in MLI, in that case to keep the cold of the Moon away from the astronauts. Most people are familiar with MLI type aluminized film from its use in Pop-Tart wrappers!

Southern Research has conducted demonstration tests that have shown that the cryo-cooler is capable of cooling materials down to -423 °F.  Southern Research is now focused on developing best practice for thermal strapping, MLI wrapping, and load fixture design.  Southern Research is actively proposing work using the cryo-cooler approach at better cost and schedule assurance to our clients.

Southern Research and Tonix Pharmaceuticals COVID-19 Vaccine Research Update

On the 16th of November, 2020, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced preliminary results for a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 (CoV-2) spike protein after vaccination. The research is part of an ongoing collaboration with Southern Research, Tonix Pharmaceuticals, and others.

Southern Research Tonix
Southern Research reports positive
immune response results with New York-based Tonix Pharmaceuticals.

In the announcement, they explain that the preliminary results produced the desired reaction.  This reaction of the skin showed that there is functional T cell immunity in the subjects and the result of the given vaccine led to the counteracting of antibodies in each of the cases .  Vaccines that bring about strong T cell responses have been established to provide prolonged and enduring immunity and the ability to block continued transmission.

Dr. Lederman, President and Chief Executive Officer of Tonix, commented that their hope “is to produce a vaccine that will provide long term immunity with a single dose using a proven technology that can be readily scaled up” to manufacture and distribute quickly.

Southern Research makes key leadership announcements

Southern Research has named Michael Catalano and Mark Suto, Ph.D., chief operating officer and vice president for Life Sciences, respectively. Previously, Catalano served as interim COO, and Suto was VP for Drug Discovery and interim VP for Drug Development.

Southern Research
Michael Catalano is chief operating officer of aSouthern Research.

University of Alabama at Birmingham President Ray L. Watts serves as Southern Research interim CEO and chairman.

“Michael and Mark have provided forward-thinking and effective leadership during this critical time of notable progress for SR and collaboration with UAB,” Watts said. “Solidifying these positions of leadership will enable SR to build on its strong trajectory and positive momentum.”

Catalano joined SR in 2017 as general counsel and assumed the interim COO role in 2018. As permanent COO, he will continue to manage the day-to-day operations of SR.

“I am honored to continue to serve in this role and humbled every day to work with our incredible teams at SR,” Catalano said. “I am proud of all we continue to accomplish together and excited about our future.”  

Since joining SR in 2011, Suto has developed multiple research collaborations spanning a diverse array of diseases. In his new role, he will build on ongoing efforts to unite Drug Discovery and Drug Development to optimize growth in SR’s Life Sciences portfolio and impact.

“We have made great strides in evolving drug discovery and drug development in recent years as we ensure SR is well-positioned as a modern life sciences organization,” Suto said. “We have a bright future, and I am excited for this opportunity.”

Both promotions are effective immediately.  

Southern Research
Mark Suto, Ph.D., is vice present for Life Sciences at Southern Research.

Prior to SR, Catalano was general counsel and privacy officer at Influence Health; chief operating officer, corporate secretary and general counsel for SilverStaff Inc.; vice president of finance for Caesars Entertainment Inc.; and senior development counsel for pharmacy health care provider CVS Caremark.

Suto has more than 35 years of experience working in several large pharmaceutical companies, as well as smaller biotech and venture-backed organizations. He has led multidisciplinary programs that resulted in the identification of clinical candidates in several therapeutic areas.

Southern Research, Tonix expand COVID-19 vaccine collaboration

Southern Research announced an expansion of its strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp. to include a study of immune responses to SARS-CoV-2, the virus that causes COVID-19.

This research will focus specifically on T cell immune responses to SARS-CoV-2 in volunteers who have recovered from the disease or who remain asymptomatic after exposure to COVID-19.

Raj Kalkeri, Ph.D., MBA, a senior scientist in Southern Research’s Infectious Disease Research Group, said the study’s findings will shed new light on the role that T cells – a central part of the immune system – may play in the development of a vaccine against the novel coronavirus.

“As scientists, we know that the most successful vaccines mimic and potentiate how the immune system responds to an invader,” Kalkeri said. “This additional work we are doing with Tonix will add focus to that objective.”

Southern Research
Birmingham-based Southern Research is teaming with Tonix Pharmaceuticals to study immune system responses to SARS-CoV-2, the virus that causes COVID-19.

The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct testing of the pharmaceutical company’s TNX-1800, a potential vaccine designed to protect against COVID-19.

The collaboration on vaccine development was announced in February 2020. Results from this testing are expected in the fourth quarter of 2020, followed by subsequent human trials of TNX-1800.

“The data we plan to collect from recovered and asymptomatic COVID-19 volunteers is expected to inform vaccine development on how to safely provide to vaccine recipients the same immune responses that others got from recovering from actual CoV-2 infection,” said Tonix CEO and President Seth Lederman, M.D.

T CELL RESPONSES

Lederman said TNX-1800, the firm’s leading COVID-19 vaccine candidate, is designed to elicit a predominant T cell response, along with some antibody response. Three other early candidates in the company’s vaccine portfolio are designed to elicit an almost pure T cell response, he added.

“The features of a protective immune response to SARS-CoV-2 remain unknown. But since SARS-CoV-2 is a virus, we believe that T cell responses, in particular T Helper Type 1, or TH1 responses, will play an important if not dominant role in protecting against serious illness from COVID-19,” Lederman said.

Read Tonix’s full announcement.

COVID-19
Raj Kalkeri, Ph.D., is a senior scientist in Southern Research’s Infectious Disease Research Group.

Southern Research Drug Development division scientists joining Kalkeri on the collaboration with Tonix are Elizabeth Wonderlich, Ph.D., senior scientist; John Farmer, Ph.D., manager of immunoassay; and Fusataka Koide, director of virology.

“We are looking forward to a timely completion of this study, utilizing readouts from a variety of assays that can provide information about TH1 or other types of immunity,” Kalkeri said.

Birmingham-based Southern Research, which has considerable experience in infectious disease research, has long been a leader in the evaluation of vaccine candidates and possible therapeutics for emerging biological threats.

The COVID-19 pandemic is a serious global health treat, with the World Health Organization reporting more than 14 million cases confirmed worldwide, causing  600,000 deaths.

As of July 21, more than 3.8 million COVID-19 cases have been confirmed in the United States, with over 140,369 deaths, according to the U.S. Department of Health and Human Services.

 

Support Southern Research’s work against COVID-19Donate today.

 

 

 

 

Southern Research’s screening center searches for clues to COVID-19 treatments

Inside a high-tech laboratory at Southern Research, a team led by Robert Bostwick, Ph.D., is screening vast numbers of compound samples to identify agents that could become a new treatment for COVID-19, the disease caused by the novel coronavirus.

Bostwick is director of Southern Research’s state-of-the-art High-Throughput Screening (HTS) Center, which features advanced robotic equipment and a collection of around 750,000 compounds for rapid, accurate testing.

Since 2006, the HTS Center has screened an average of 3.3 million compounds each year in biochemical, bacterial, cell-based, and antiviral assays. The center’s scientists have been working on coronaviruses for the past six years.

Since the pandemic began earlier this year, Bostwick’s team has screened compound samples for pharmaceutical companies, biotech firms and key government agencies. It’s also screened FDA-approved drugs to see if they show potential activity against the pathogen.

Bostwick, who joined the Birmingham-based research organization in 2013 after working for AstraZeneca and other bioscience companies, talks about the capabilities of the HTS Center and how his team is making a contribution to the fight against COVID-19.

What is the goal of Southern Research’s screening program as it relates to the novel coronavirus?

Southern Research
Southern Research’s High Throughput Screening Center features advanced robotic equipment and a collection of around 750,000 compounds for rapid, accurate testing.

The goal is to discover drugs that can be used as therapeutic treatments for COVID-19. By screening compounds in our HTS Center, we can rapidly identify those that exhibit antiviral effects against SARS-CoV-2, the virus that causes the disease.

These compounds can then be used as starting points for the development of new therapeutic agents.

If the screen identifies compounds that are already approved as drugs to treat various other diseases, they can potentially be repurposed for treating COVD-19.

What are Southern Research’s key capabilities in screening compounds as part of the drug discovery process?

Using automated robotic systems to perform testing is a key capability to enable high throughput screening. Southern Research’s HTS Center can also conduct screens that require containment of highly infectious agents and is internationally known for its infectious disease capabilities.

The HTS Center has screened over 15 million compound samples in over 50 different infectious disease assays. It currently serves as the screening core for the NIH-funded Antiviral Drug Discovery and Development Center (AD3C), based at UAB, our close collaborator on many projects.

 Describe the scope of Southern Research’s activities in screening compounds against COVID-19.

Southern Research COVID-19 screening
Dr. Robert Bostwick directs the High Throughput Screening Center at Southern Research.

For the past six years we have been conducting a drug discovery effort for coronaviruses through the AD3C and have expanded that effort to include SARS-CoV-2.

In addition, we are providing screening services to several major pharmaceutical companies, over two dozen biotech companies, the Gates Foundation and the National Center for Advancing Translational Sciences, which is part of the NIH.

Since early April, we have been generating over 30,000 data points weekly in screens to identify compounds with antiviral activity against SARS-CoV-2.

How many compounds has Southern Research screened as part of its internal COVID-19 research program?

Prior to the outbreak of COVID-19, we had already screened over 305,000 compounds against SARS in support of the AD3C coronavirus drug discovery project. After the outbreak, we tested the hits from that campaign against SARS-CoV-2 and identified several compounds with antiviral effects against both viruses. We are making and testing dozens of new compounds for that program every month.

We also screened a collection containing FDA-approved drugs and late-stage clinical candidates against SARS-CoV-2 to identify drugs with potential for repurposing.

Why is ‘drug repurposing’ a smart approach in this pandemic?

It takes years to invent and bring a new drug to market. Since the safety profile of marketed drugs is already known, a drug need only be evaluated in clinical studies to determine if it can effectively treat a disease other than the one for which it is marketed.

Therefore, in a pandemic, it is much quicker to repurpose existing drugs for use in combating the pathogen as opposed to inventing an entirely new drug.

 

Support Southern Research’s work against COVID-19Donate today.

 

Scientist Mark Suto: Southern Research intensifying therapeutic efforts to combat COVID-19

Responding to the COVID-19 pandemic, Southern Research has accelerated its drug discovery and development activities to identify and test vaccines and therapeutics against coronavirus that could save lives and help restore the nation’s hard-hit economy.

A key figure in this effort is Mark J. Suto, Ph.D., vice president of the Drug Discovery division and interim vice president of the Drug Development division at Southern Research.

Suto, who has made wide-ranging contributions to pharmaceutical research and drug discovery efforts during a 35-plus year career, has worked in large pharmaceutical companies, as well as smaller biotech and venture-backed firms.

Since joining Southern Research in 2011, Suto has engaged in multiple research collaborations spanning a diverse range of diseases and therapeutic areas, including rare and neglected diseases.

In a question-and-answer format, Suto discusses Southern Research’s multi-pronged effort to fight COVID-19, the virus causing the serious, sometimes fatal respiratory illness.

COVID-19
Mark Suto, Ph.D., is vice president of Drug Discovery and interim vice president of Drug Development at Southern Research.

What is Southern Research doing to develop new therapies and vaccines against COVID-19?

 As part of our long history with the identification of new medicines to treat life-threatening diseases such as cancer and HIV, we have channeled our resources to address the COVID-19 pandemic. For example, we are collaborating with several pharmaceutical companies to identify new research tools and vaccines. We recently announced a collaboration with Tonix, a biopharmaceutical firm, to test its vaccine candidate.

As part of a large consortium funded by the National Institute of Allergy and Infectious Diseases (NIAID) involving our partnering institution, the University of Alabama at Birmingham (UAB), we are building upon our ongoing research on highly pathogenic coronaviruses to develop new therapies. We are also working in partnership with UAB to test compounds for antiviral activity against COVID-19.​

How did Southern Research begin its work?

 From the onset of the COVID-19 threat, Southern Research quickly worked with the Centers for Disease Control and Prevention (CDC) and other government agencies to obtain the virus for experimental testing. Due to the nature of the virus (i.e., ability to rapidly spread and cause infection), handling requires highly specialized facilities available at Southern Research. After having obtained the virus, intense research has been initiated and is ongoing which aims to identify effective therapies.

Has Southern Research activated an internal COVID-19 program?

 In addition to these activities, we established an internal research program to identify known drugs that will be effective against this new threat. In the case of combating COVID-19, speed is of the essence given wide-reaching consequences. It is well known that the development of new drugs is a costly endeavor and requires years of research. Southern Research has taken a non-traditional approach of drug discovery which could result in the identification of new therapies in a period of months rather than years.

What is Southern Research’s strategy in searching for new therapies?

 Our approach, referred to as ‘drug repurposing’, consists of developing a rapid method or screen to determine whether there are already FDA-approved drugs that would be effective against COVID-19. We’ve tested more than 3,500 drugs and have identified 12 which are highly active against the virus. An interesting fact is that those that have been identified were all originally developed not as antivirals but rather for a wide range of medical conditions.

What are the next steps in this process?

 Next, we need to further evaluate these drugs under several various conditions to identify those with clinical promise. Also, since all of these compounds are approved for use in people, clinical trials could be initiated very quickly.

 

Support Southern Research’s work against COVID-19. Donate today.

Southern Research’s Johns tapped for Alabama Engineering Hall of Fame

Southern Research Vice President of Engineering Michael D. Johns has been inducted into the State of Alabama Engineering Hall of Fame in recognition of his contributions to game-changing technologies in support of NASA, the Department of Defense and others.

Since joining Birmingham-based Southern Research in 1997, Johns has established a reputation as an expert on advanced composite materials, played an important role in the development of strategic defense technologies, and expanded the scope of the organization’s engineering activities.

Those who have worked with Johns say he has made lasting impacts on the engineering field in Alabama.

“Johns represents the best of what it means to be an engineer — his technical expertise is deep, his leadership has been proven time and time again, and his actions to help others make him someone worthy of emulation,” said C. Stephen Cornelius, senior vice president at Kord Technologies Inc. in Huntsville.

Southern Research
Nicole Faulk, chair of the State of Alabama Engineering Hall of Fame Board of Directors, presents Southern Research’s Mike Johns with a plaque at an induction ceremony, Feb. 22, 2020. (Image: Alabama Engineering Hall of Fame/Matthew Wood)

Robert M. Lightfoot Jr., vice president for strategy and business development at Lockheed Martin Space, worked with Johns while at NASA and considered him an ideal industry partner.

“His engineering depth made him a strong voice when advocating for key technologies this nation needed to develop,” Lightfoot said. “Mike demonstrates an innate ability to effectively communicate the value of engineering technology and research at all levels.”

Johns has served as a member of the NASA Advisory Council Technology, Innovation & Engineering Committee since 2014, supporting the advisory needs of the NASA administrator, the Office of the Chief Technologist, and NASA Mission Directorates.

He joins Coultas “Colt” Pears, an innovator who led the development of Southern Research’s high-temperature materials laboratory, in the Alabama Engineering Hall of Fame. The lab, renamed for Pears, and Southern Research itself are also recognized in the Hall of Fame.

In 2017, Southern Research’s Stuart Starrett, who is credited with making significant contributions to the development of reentry nosetips for U.S. ballistic missile systems, was inducted into the Alabama Engineering Hall of Fame.

Starrett, who remains a consultant, said the Engineering division, under Johns’ leadership, continues to “celebrate technological successes in landmark contributions to our nation’s defense” while also expanding in other areas.

Johns’ induction into Alabama Engineering Hall of Fame took place Saturday, Feb. 22, at the Bryant Conference Center at The University of Alabama.

The Hall of Fame was founded in 1987 to celebrate the outstanding accomplishments and contributions of individuals, projects, and corporations/institutions that have brought and continue to bring significant recognition to the State of Alabama.

ENGINEERING LEADERSHIP

Johns has served as vice president of Southern Research’s Engineering division since 2004. Under his leadership, the unit has grown in technical fields including advanced materials, aerospace engineering, composite structures manufacturing, automotive technology development, nuclear energy technologies, airborne sensor systems, hypersonics and additive manufacturing.

Southern Research
Mike Johns, vice president of Engineering at Southern Research, speaks during an induction ceremony for the State of Alabama Engineering Hall of Fame, Feb. 22, 2020. (Image: Alabama Engineering Hall of Fame/Matthew Wood)

Steve Cook, executive vice president at Huntsville-based Dynetics, said he has gotten to know Johns through work on the U.S. Navy’s hypersonic glide body program.

“Mike’s engineering skills and leadership approach have already enabled extensive technological innovation in hypersonic glide body technologies, specifically reentry thermal protection systems,” Cook said. “His involvement will undoubtedly continue to shape the hypersonics renaissance in the country, helping the United States to once again become a world leader in advanced hypersonic flight systems.”

At Southern Research, Johns has directed and managed high-profile research and commercial projects in areas such as solar energy, municipal solid waste to energy conversion, water research, automotive engineering, space exploration  and  hypersonics.

During his tenure at Southern Research, Johns also directed the organization’s Transportation Systems division and served as department head of the Materials Characterization Group. In this latter role, he was responsible for materials research programs for NASA and the Department of Defense, as well as emerging areas of automotive research in the Southeast.

He received a bachelor’s degree in mechanical engineering from The University of Alabama and an MBA from UA’s Manderson Graduate School of Business. He is of the current chair of the University of Alabama’s College of Engineering Leadership Board and the member of the engineering leadership board at the University of Alabama at Birmingham, among many other departmental advisory boards across the state.

 

 

Southern Research, Tonix team to develop potential vaccine against new coronavirus

Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, to support the development of a vaccine, TNX-1800, against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform.

Tonix is developing TNX-801 – a live horsepox virus vaccine for percutaneous administration — as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a vaccine against monkeypox.

Tonix’s proprietary horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious agents.

Southern Research and Tonix said the new research collaboration will develop and test a potential horsepox vaccine that expresses protein from the virus that causes COVID, a SARS-CoV-2, to protect against the disease.

Southern Research Tonix
Southern Research will test potential vaccines against the novel coronavirus under a research collaboration with New York-based Tonix Pharmaceuticals.

There are currently no vaccines to protect against COVID-19, which may cause serious complications. The SARS-CoV-2 is reportedly highly infectious and is associated with a significant rate of mortality.

“We look forward to this collaboration to advance a potential COVID-19 vaccine,” said Scott Goebel, a senior scientist in Southern Research’s Drug Development division and principal investigator of the project.

Birmingham-based Southern Research, which has considerable experience in infectious disease research, has long been a leader in the evaluation of vaccine candidates and possible therapeutics for emerging biological threats.

Goebel has previously worked on vaccinia and orthopoxvirus vaccines for other conditions and has studied coronaviruses.

TESTING VACCINE CONSTRUCTS

Under the terms of the research collaboration, Southern Research will test one or more vaccine constructs in the Tonix horsepox vector that express one or more proteins or protein fragments from COVID-19.

The collaboration seeks to leverage Tonix’s horsepox vaccine technology that was originally developed to protect against smallpox but has capabilities as a vector for other infectious diseases.

Tonix has previously reported that horsepox has efficacy as a vaccine and good tolerability in mice and cynomolgus macaques. Horsepox is closely related to vaccinia vaccines, which are a group of orthopoxviruses that have been used as smallpox vaccines. Some vaccinia vaccines have been engineered to express coronavirus proteins and to elicit vaccine responses successfully in the past.

“Although vaccinia vectors are available, different orthopoxvirus strains may behave differently as vectors in part because of their different repertoire of genes that modulate immune responses and host range,” said Dr. Seth Lederman, CEO of Tonix Pharmaceuticals. “Potential advantages of horsepox are the strong immunogenicity we observed in macaques and mice with good tolerability.

“The protein synthesis connected with a replicating live virus vaccine provides direct antigen presentation, which can stimulate cellular immunity in addition to humoral immunity,” added Dr. Lederman, formerly an associate professor at Columbia University who made significant original contributions to immunology.

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat pain, addiction and psychiatric conditions.

To see the company’s detailed announcement on the collaboration, click here.

Southern Research expands STEM Ambassadors program to train new teachers

Southern Research continues to expand its efforts to transform STEM education in schools across Alabama.

The organization has revamped its STEM Ambassadors program, with an eye toward training a new crop of math and science teachers.

“Across the nation, there’s a huge shortage of qualified math and science teachers, just as there’s a shortage of STEM workers in general, so we are trying to help address that issue,” said Kathryn Lanier, Ph.D., Southern Research’s STEM Education Outreach director.

When it started several years ago, the STEM Ambassadors program was a summer program, in which University of Alabama at Birmingham students with an interest in STEM fields helped with summer camps for high school students at Southern Research’s state-of-the-art STEM Lab in Birmingham.

Southern Research
Southern Research STEM Ambassador Amber Lakey, a freshman mathematics major at UAB, works with students from D.A. Smith Middle School in Ozark. The STEM Ambassadors program is helping to prepare the next generation of math and science teachers in Alabama.

But now, STEM Ambassadors are working throughout the year, helping with field trips from high schools across Alabama.

Southern Research has partnered with UAB Teach, a program that allows UAB students majoring in STEM fields to take education courses as well. And when they graduate with a STEM degree, they will also be certified to teach in high school classrooms.

This semester, Southern Research has 10 STEM Ambassadors who are also a part of UAB Teach. They are paid by the hour, and they are gaining valuable training for their future careers.

“It’s a win-win for us,” Lanier said. “We need extra hands to help us facilitate our field trip experiences. It also provides these future educators with exposure to a very different learning environment – one that allows students to apply their content knowledge to tackle real-world problems.”

“PERFECT EXPERIENCE”

One of the newest STEM Ambassadors is Amber Lakey, a UAB freshman who is majoring in mathematics.

“I knew that working with kids in such an intellectually stimulating environment, the STEM Lab, would be an incredible experience that would hopefully prepare me for my career as a teacher,” she said.

After graduation, Lakey wants to teach high school math and later become involved in administration.

“The STEM Ambassador program is the perfect experience for me, since I want to teach,” she said. “As I work through my education courses, I’ve already begun to notice how much easier it is for me to connect with the students; it’s a skill that I take on with ease now. When I am a teacher, I will be able to apply these experiences to engage with students and encourage them to be passionate about STEM.”

Southern Research
Southern Research STEM Ambassador Savannah Teague, a freshman Immunology major at UAB, talks to a 6th-grade student from Hartselle Intermediate School.

Lakey said she has loved her STEM Ambassador experience so far.

“When the students are there, I’m super busy running around to be involved with each group, ask questions and encourage them to keep trying new things during the experiments, and I enjoy every second of it. There are some jobs that are just that – a job. This honestly feels nothing like a job. I have so much fun with the students,” she said.

MAKING CONNECTIONS

Southern Research is in the middle of a robust schedule of about 80 field trips for the 2019-2020 school year. Field trips include hands-on experiments in the STEM Lab and cover a variety of topics, such as tracking and diagnosing infectious diseases and transferring renewable resources into electricity.

Lanier said another benefit for the STEM Ambassadors is the connections they are making with educators and administrators who are accompanying their students on the field trips, which could help with future job placements.

Over time, she expects the STEM Ambassadors to become comfortable with leading students through the various steps of the field trips on their own.

“The hope is that by the end of the semester, or next year, they’ll be confident enough to lead certain parts of the field trip, if they want to,” Lanier said. “And hopefully they will become teachers themselves and bring their students back here for a field trip.”

Southern Research
STEM Ambassador Tyhre Heath, a junior mathematics major at UAB, speaks to students from Ozark’s D.A. Smith Middle School during a visit to Southern Research.

Researcher: Indicator points to active flu season, urges vaccination

Are we headed for a rough flu season? Southern Research scientist Landon Westfall, who specializes in influenza and vaccines, says one indicator is flashing a warning sign that the months ahead could bring flu-related misery to many Americans.

The reason: Australia experienced a fairly severe flu season. That suggests the same fate could be in store for the North Hemisphere. It’s precisely what happened in 2017, when the H3N2 flu strain clobbered Australia. In the U.S., almost 80,000 people died during that flu season.

“It’s too early to precisely gauge how severe this flu season will be for us,” said Westfall, Ph.D., associate director, influenza, in Southern Research’s Drug Development division. “But you can get an idea from how it unfolded in Australia and New Zealand. They had a relatively hard flu season this year. This often predicts we’re likely to have a severe one as well.”

Westfall said a change in how flu vaccines are being produced this year has the potential to offer increased protection. The vaccine viruses were grown in cell cultures, rather than in chicken eggs, which should reduce the risk of mutations that can lower the vaccine’s effectiveness.

“This approach should make the vaccine a better match for the circulating, ‘wild type’ flu strains,” he said. “It makes for a more stable vaccine.”

INCREASING ACTIVITY

Southern Research flu vaccine
Landon Westfall is an infectious disease scientist at Southern Research.

Levels of influenza-like illnesses have been increasing across the U.S., particularly in the South. According to the Centers for Disease Control and Prevention (CDC), high rates of influenza-like illness were being reported in the five states stretching from Georgia to Texas, including Alabama, as of late November.

The Alabama Department of Public Health reported in early December that significant influenza activity has been detected throughout the state.

Westfall — who advises everyone to get a flu shot now, if they haven’t done so already — says influenza activity typically begins to spike around this time of year.

“Right now, the level is low, but it will increase pretty dramatically over the next four to six weeks,” he said. “Once we start getting into holiday season, and people start gathering together, it will pick up.”

While Australia’s 2019 flu season didn’t match 2017 in severity, it was an unusually tough one, with the dominant strain again being H3N2, which is blamed for more hospitalizations and deaths than other strains.

Australian health authorities reported laboratory-confirmed flu cases reached the nation’s highest recorded level during the 2019 season. The number of deaths attributed to the flu — 662 — was higher than normal but trailed the total of 745 from two years earlier.

Across the U.S., the 2017-18 influenza season was brutal, with nearly 49 million Americans sickened by the flu and almost 1 million of them ending up in the hospital. The death toll was estimated at 79,400, according to the CDC.

The nation’s most severe flu outbreak since the 2009 global pandemic was worsened by the fact that the seasonal flu vaccine was less effective against the H3N2 strain than usual.

While it’s too early to assess how much protection this year’s vaccine will offer, Westfall said it’s a good idea to roll up your sleeve and get the shot immediately. The vaccine is designed to protect against four different virus strains.

“I always tell people that regardless of how effective the vaccine is, you should still get it. Even though it may not be 100 percent protective, it will still lessen the effects of the flu. And if you’re elderly or very young, it might be the difference between life and death,” he said.

INFLUENZA PROGRAMS

Birmingham-based Southern Research has been heavily involved in U.S. government influenza programs since 2004, when H5N1, or bird flu, emerged as a pandemic threat. Since 2009, the organization has supported the government as a primary provider of flu vaccine testing and support.

Southern Research has worked extensively on influenza projects in support of clinical trials for the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Disease (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

Read a story about Southern Research vaccine research.